| Baricitinib plus remdesivir for hospitalized adults with Covid-19 AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... New England Journal of Medicine 384 (9), 795-807, 2021 | 1770 | 2021 |
| Baricitinib versus placebo or adalimumab in rheumatoid arthritis PC Taylor, EC Keystone, D Van Der Heijde, ME Weinblatt, ... New England Journal of Medicine 376 (7), 652-662, 2017 | 874 | 2017 |
| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 671 | 2021 |
| Baricitinib in patients with refractory rheumatoid arthritis MC Genovese, J Kremer, O Zamani, C Ludivico, M Krogulec, L Xie, ... New England Journal of Medicine 374 (13), 1243-1252, 2016 | 649 | 2016 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial DJ Wallace, RA Furie, Y Tanaka, KC Kalunian, M Mosca, MA Petri, ... The Lancet 392 (10143), 222-231, 2018 | 486 | 2018 |
| Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment R Fleischmann, M Schiff, D van der Heijde, C Ramos‐Remus, A Spindler, ... Arthritis & Rheumatology 69 (3), 506-517, 2017 | 422 | 2017 |
| Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study M Dougados, D van der Heijde, YC Chen, M Greenwald, E Drescher, ... Annals of the rheumatic diseases 76 (1), 88-95, 2017 | 405 | 2017 |
| Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients J Stebbing, V Krishnan, S de Bono, S Ottaviani, G Casalini, ... EMBO molecular medicine 12 (8), e12697, 2020 | 284 | 2020 |
| Symposium on ‘Nutrition and health in children and adolescents’ Session 1: Nutrition in growth and development Nutrition and bone growth and development: A meeting of the … A Prentice, I Schoenmakers, MA Laskey, S De Bono, F Ginty, ... Proceedings of the Nutrition Society 65 (4), 348-360, 2006 | 268 | 2006 |
| Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or … EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ... The Lancet Respiratory Medicine 10 (4), 327-336, 2022 | 162 | 2022 |
| Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19 JT Sims, V Krishnan, CY Chang, SM Engle, G Casalini, GH Rodgers, ... Journal of Allergy and Clinical Immunology 147 (1), 107-111, 2021 | 162 | 2021 |
| Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study EC Keystone, PC Taylor, Y Tanaka, C Gaich, AM DeLozier, A Dudek, ... Annals of the rheumatic diseases 76 (11), 1853-1861, 2017 | 112 | 2017 |
| Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, ... The lancet respiratory medicine 10 (9), 888-899, 2022 | 87 | 2022 |
| ACTT-2 Study Group Members AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ... Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J …, 2021 | 60 | 2021 |
| Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies PC Taylor, JM Kremer, P Emery, SH Zuckerman, G Ruotolo, J Zhong, ... Annals of the Rheumatic Diseases 77 (7), 988-995, 2018 | 56 | 2018 |
| Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation CO Bingham, CL Gaich, AM DeLozier, KD Engstrom, AN Naegeli, ... Trials 20, 1-8, 2019 | 51 | 2019 |
| Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... medRxiv, 2021 | 50* | 2021 |
| A segment of cold shock protein directs the folding of a combinatorial protein S de Bono, L Riechmann, E Girard, RL Williams, G Winter Proceedings of the National Academy of Sciences 102 (5), 1396-1401, 2005 | 50 | 2005 |
| Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple … T Dörner, Y Tanaka, MA Petri, JS Smolen, DJ Wallace, ER Dow, RE Higgs, ... Lupus science & medicine 7 (1), e000424, 2020 | 48 | 2020 |
| Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: Results of a phase 3 study PC Taylor, EC Keystone, D van der Heijde, Y Tanaka, T Ishii, K Emoto, ... SWISS MEDICAL WEEKLY 146, 9S-9S, 2016 | 44 | 2016 |
